1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Factor Xa

Factor Xa

Fxa

Factor Xa, a trypsin-like serine protease, is situated at the critical juncture between the intrinsic and extrinsic pathways, catalyzing the conversion of prothrombin to thrombin, and hence plays a pivotal role in the final common pathway of the cascade and has become an important target in the discovery and development of new anticoagulants. Factor Xa is a key protease of the coagulation pathway whose activity is known to be in part modulated by binding to factor Va and sodium ions.

Blood coagulation involves a complex cascade of enzymatic reactions, ultimately generating fibrin, the basis of all blood clots. This cascade is comprised of two arms, the intrinsic and extrinsic pathways which converge at factor Xa to form the common pathway. Factor Xa activates prothrombin to thrombin, which in turn catalyzes the conversion of fibrinogen to fibrin.

Factor Xa Related Products (63):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-17567A
    Heparin sodium salt
    Inhibitor ≥98.0%
    Heparin sodium salt (Sodium heparin) is an anticoagulant which binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin factor IIa and factor Xa. Heparin sodium salt significantly inhibits exosome-cell interactions.
    Heparin sodium salt
  • HY-17567C
    Heparin sodium salt (MW 15kDa)
    Inhibitor
    Heparin sodium salt (MW 15kDa) (Sodium heparin (MW 15kDa)) is a polymer of Heparin with the molecular weight of 15kDa. Heparin sodium salt is an anticoagulant which binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin factor IIa and factor Xa.
    Heparin sodium salt (MW 15kDa)
  • HY-50667
    Apixaban
    Inhibitor 99.99%
    Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively. Apixaban is in development for the prevention and treatment of various thromboembolic diseases.
    Apixaban
  • HY-50903
    Rivaroxaban
    Inhibitor 99.93%
    Rivaroxaban (BAY 59-7939) is a highly potent, selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM).
    Rivaroxaban
  • HY-10264
    Edoxaban
    Inhibitor 99.59%
    Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research.
    Edoxaban
  • HY-P4245
    D-Pro-Phe-Arg-Chloromethylketone
    Inhibitor 98.95%
    D-Pro-Phe-Arg-Chloromethylketone, a inhibitor of coagulation factor XII and plasma kallikrein, plays an important role in thrombosis and inflammation.
    D-Pro-Phe-Arg-Chloromethylketone
  • HY-P6023A
    D-Leu-Pro-Arg-Rh110-D-Pro TFA
    Chemical
    D-Leu-Pro-Arg-Rh110-D-Pro TFA is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro TFA consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro TFA can be used to detect FXIa activity.
    D-Leu-Pro-Arg-Rh110-D-Pro TFA
  • HY-P6023B
    D-Leu-Pro-Arg-Rh110-D-Pro acetate
    Modulator
    D-Leu-Pro-Arg-Rh110-D-Pro acetate is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro acetate consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro acetate can be used to detect FXIa activity.
    D-Leu-Pro-Arg-Rh110-D-Pro acetate
  • HY-B0597
    Fondaparinux sodium
    Inhibitor ≥98.0%
    Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor.
    Fondaparinux sodium
  • HY-137431
    Asundexian
    Inhibitor 99.93%
    Asundexian (BAY 2433334) is an orally active coagulation factor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa in buffer with an IC50 of 1 nM.
    Asundexian
  • HY-125856
    Milvexian
    Inhibitor 98.02%
    Milvexian is an orally bioavailable, small-molecule, reversible, direct antagonists of factor Xia, with the Ki of 0.11, 0.38, 0.64, 490, 350 nM for human, rabbit, dog, rat, mouse, respectively. Milvexian shows anti-thrombosis activity in vitro and in vivo, and can be used for thrombus study.
    Milvexian
  • HY-10264B
    Edoxaban tosylate monohydrate
    Inhibitor 99.91%
    Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research.
    Edoxaban tosylate monohydrate
  • HY-10268
    Betrixaban
    Inhibitor 98.10%
    Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban shows antithrombotic effect.
    Betrixaban
  • HY-109509
    Enoxaparin
    Inhibitor
    Enoxaparin (PK 10169), a low-molecular-weight heparin (LMWH) derivative. Enoxaparin exerts anticoagulant activity through antithrombin III, an endogenous inhibitor of factor Xa and thrombin IIa. Enoxaparin protect the rat hippocampus against TBI (traumatic brain injury) via antioxidant and anti-inflammatory properties. Enoxaparin can be used for the research of deep vein thrombosis (DVT), pulmonary embolism, TBI and COVID-19.
    Enoxaparin
  • HY-B0385
    Gabexate mesylate
    Inhibitor 99.14%
    Gabexate mesylate (FOY) is is a competitive and non-antigenic synthetic inhibitor of trypsin-like serine proteinases. Gabexate mesylate inhibits human thrombin, urokinase, plasmin, and Factor Xa with Kis of 0.97, 1.3, 1.6, and 8.5 μM, respectively. Gabexate mesylate binds to human and bovine tryptase with Kis of 3.4 nM and 18 μM, respectively. Gabexate mesylate exerts an anticoagulant effect on the clotting activity of thrombin and has anti-inflammatory effect by viainhibition of NF-κB, proinflammatory cytokines, and nitric oxide. Gabexate mesylate is used for pancreatitis and disseminated intravascular coagulation.
    Gabexate mesylate
  • HY-P99415
    Abelacimab
    Inhibitor 98.63%
    Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies.
    Abelacimab
  • HY-P99631
    Garadacimab
    Inhibitor
    Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research.
    Garadacimab
  • HY-70035
    Otamixaban
    Inhibitor 98.08%
    Otamixaban(FXV673) is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa.
    Otamixaban
  • HY-118969
    BMS-262084
    Inhibitor 98.06%
    BMS-262084 is a potent, selective and irreversible inhibitor of factor XIa, with an IC50 of 2.8 nM against human factor XIa. BMS-262084 also inhibits human tryptase (IC50=5 nM). BMS-262084 exhibits antithrombotic effects.
    BMS-262084
  • HY-14853
    Darexaban
    Inhibitor 99.60%
    Darexaban (YM150) is a potent, selective and orally active factor Xa (FXa) inhibitor with an IC50 of 54.6 nM. Darexaban shows high selectivity against other related serine proteases, such as trypsin, thrombin, and kallikrein. Darexaban has anticoagulant and antithrombotic effects.
    Darexaban